natgillin/translations-raw huggingface dataset:
For patients in whom the dose was increased to >7 mg/kg, dose reduction to 7 mg/kg or less is recommended when LIC is <7 mg Fe/g dw or serum ferritin is ≤2,000 µg/l. 
U bolesnika u kojih je doza povećana na >7 mg/kg, preporučuje se smanjenje doze na 7 mg/kg ili manje kad je LIC <7 mg Fe/g težine suhog tkiva jetre ili je serumski feritin ≤2000 µg/l.
Approximate tablet dimensions 12 mm x 3.6 mm. 
Približne dimenzije tablete 12 mm x 3,6 mm.
Approximate tablet dimensions 10.7 mm x 4.2 mm. 
Približne dimenzije tablete 10,7 mm x 4,2 mm.
Approximate tablet dimensions 20 mm x 5.6 mm. 
Približne dimenzije tablete 20 mm x 5,6 mm.
If only very poor haemosiderosis control is achieved at doses up to 30 mg/kg, a further increase (to a maximum of 40 mg/kg) may not achieve satisfactory control, and alternative treatment options may be considered. 
Ako je pri dozama do 30 mg/kg postignuta vrlo slaba kontrola hemosideroze, moguće je da se zadovoljavajuća kontrola neće postići ni daljnjim povećanjem doze (na najviše 40 mg/kg) pa je u tom slučaju potrebno razmotriti druge mogućnosti liječenja.
In patients not adequately controlled with doses of 30 mg/kg (e.g. serum ferritin levels persistently above 2,500 µg/l and not showing a decreasing trend over time), doses of up to 40 mg/kg may be considered. 
U bolesnika neodgovarajuće kontroliranih dozama od 30 mg/kg (tj. razine feritina u serumu su stalno iznad 2500 µg/l i ne pokazuju trend opadanja tijekom vremena) može se razmotriti primjena doza do 40 mg/kg.
14 mg/kg/day 20 mg/kg/day 
14 mg/kg/dan 20 mg/kg/dan
Exjade 90 mg granules deferasirox 
Exjade 90 mg granule deferasiroks
EXJADE film-coated tablets may be taken either on an empty stomach or with a light meal, preferably at the same time each day (see sections 4.2 and 5.2). 
EXJADE filmom obložene tablete mogu se uzimati ili na prazan želudac ili uz lagani obrok, po mogućnosti svakoga dana u isto vrijeme (vidjeti dijelove 4.2 i 5.2).
EXJADE contains lactose 
EXJADE sadrži laktozu
• If you experience a combination of any of the following symptoms: rash, red skin, blistering of the lips, eyes or mouth, skin peeling, high fever, flu-like symptoms, enlarged lymph nodes, 
• Ako primijetite kombinaciju bilo kojih od sljedećih simptoma: osip, crvenu kožu, mjehuriće na usnicama, očima ili u ustima, ljuštenje kože, vrućicu, simptome nalik gripi, povećane limfne čvorove (znakovi teških kožnih reakcija),
EXJADE film-coated tablets demonstrate higher bioavailability compared to the EXJADE dispersible tablet formulation. 
EXJADE filmom obložene tablete pokazuju višu bioraspoloživost u usporedbi s formulacijom lijeka EXJADE u obliku tableta za oralnu suspenziju.
INTERMEDIATE CARTON OF MULTIPACK (without blue box) 
SREDNJA KUTIJA VIŠESTRUKOG PAKIRANJA (bez plavog okvira)
The patient's serum ferritin should be monitored during and after the combination, and the dose of EXJADE adjusted if necessary. 
Tijekom i nakon primjene kombinacije potrebno je pratiti serumski feritin u bolesnika te prilagoditi dozu lijeka EXJADE ako je potrebno.
Starting dose The recommended initial daily dose of EXJADE film-coated tablets is 14 mg/kg body weight. 
Početna doza Preporučena početna dnevna doza EXJADE filmom obloženih tableta je 14 mg/kg tjelesne težine.
EXJADE 360 mg film-coated tablets 
EXJADE 360 mg filmom obložene tablete
EXJADE 90 mg granules in sachet EXJADE 180 mg granules in sachet EXJADE 360 mg granules in sachet 
EXJADE 90 mg granule u vrećici EXJADE 180 mg granule u vrećici EXJADE 360 mg granule u vrećici
Starting dose The recommended initial daily dose of EXJADE granules is 14 mg/kg body weight. 
Početna doza Preporučena početna dnevna doza EXJADE granula je 14 mg/kg tjelesne težine.
• EXJADE 125 mg tablets are stamped “J 125” on one side and “NVR” on the other. 
• EXJADE 125 mg tablete na jednoj strani imaju otisnutu oznaku „J 125“, a na drugoj strani
28 mg/kg/day 40 mg/kg/day 
28 mg/kg/dan 40 mg/kg/dan
EXJADE 125 mg dispersible tablets Packs containing 28, 84 or 252 dispersible tablets. 
EXJADE 125 mg tablete za oralnu suspenziju Pakiranje sadrži 28, 84 ili 252 tablete za oralnu suspenziju.
Breast-feeding is not recommended during treatment with EXJADE. 
Tijekom liječenja lijekom EXJADE ne preporučuje se dojenje.
EXJADE dispersible tablets must therefore be taken on an empty stomach at least 30 minutes before food, preferably at the same time each day (see sections 4.2 and 5.2). 
Stoga se EXJADE tablete za oralnu suspenziju moraju uzimati na prazan želudac, najmanje 30 minuta prije jela, po mogućnosti svakoga dana u isto vrijeme (vidjeti dijelove 4.2 i 5.2).
EXJADE 180 mg film-coated tablets 
EXJADE 180 mg filmom obložene tablete
EXJADE 90 mg granules in sachet EXJADE 180 mg granules in sachet EXJADE 360 mg granules in sachet Deferasirox 
EXJADE 90 mg granule u vrećici EXJADE 180 mg granule u vrećici EXJADE 360 mg granule u vrećici deferasiroks
EXJADE 90 mg film-coated tablets EXJADE 180 mg film-coated tablets EXJADE 360 mg film-coated tablets Deferasirox 
EXJADE 90 mg filmom obložene tablete EXJADE 180 mg filmom obložene tablete EXJADE 360 mg filmom obložene tablete deferasiroks
3.5 - 7 mg/kg/day Up to 28 mg/kg/day 
3,5 - 7 mg/kg/dan Do 28 mg/kg/dan
Approximate tablet dimensions 15 mm x 4.7 mm. 
Približne dimenzije tablete 15 mm x 4,7 mm.
EXJADE 250 mg dispersible tablets Packs containing 28, 84 or 252 dispersible tablets. 
EXJADE 250 mg tablete za oralnu suspenziju Pakiranje sadrži 28, 84 ili 252 tablete za oralnu suspenziju.
3.5 - 7 mg/kg/day 5-10 mg/kg/day Decrease 
3,5 - 7 mg/kg/dan 5-10 mg/kg/dan Smanjenje
After every 3 to 6 months of treatment, a dose increase in increments of 3.5 to 7 mg/kg should be considered if the patient's LIC is ≥7 mg Fe/g dw, or if serum ferritin is consistently >2,000 µg/l and not showing a downward trend, and the patient is tolerating the medicinal product well. 
Nakon svakih 3 do 6 mjeseci liječenja potrebno je razmotriti mogućnost povećanja doze za 3,5 do 7 mg/kg ako je u bolesnika LIC ≥7 mg Fe/g težine suhog tkiva jetre, odnosno ako je serumski feritin dosljedno >2000 µg/l bez naznaka silaznog trenda, a bolesnik dobro podnosi lijek.
After every 3 to 6 months of treatment, a dose increase in increments of 5 to 10 mg/kg should be considered if the patient's LIC is ≥7 mg Fe/g dw, or if serum ferritin is consistently >2,000 µg/l and not showing a downward trend, and the patient is tolerating the medicinal product well. 
Nakon svakih 3 do 6 mjeseci liječenja potrebno je razmotriti mogućnost povećanja doze za 5 do 10 mg/kg ako je u bolesnika LIC ≥7 mg Fe/g težine suhog tkiva jetre, odnosno ako je serumski feritin dosljedno >2000 µg/l bez naznaka silaznog trenda, a bolesnik dobro podnosi lijek.
EXJADE dispersible tablets must be taken once daily on an empty stomach at least 30 minutes before food, preferably at the same time each day (see sections 4.5 and 5.2). 
EXJADE tablete za oralnu suspenziju se moraju uzimati jednom dnevno na prazan želudac, najmanje 30 minuta prije obroka, po mogućnosti u isto vrijeme svakog dana (vidjeti dijelove 4.5 i 5.2).
EXJADE 180 mg film-coated tablets EU/1/06/356/014 
EXJADE 180 mg filmom obložene tablete EU/1/06/356/014
While no increase in renal adverse events was observed after dose escalation of EXJADE dispersible tablets to doses above 30 mg/kg in clinical studies, an increased risk of renal adverse events with film-coated tablet doses above 21 mg/kg cannot be excluded. 
Premda u kliničkim ispitivanjima nije bilo opaženo povećanje bubrežnih štetnih događaja nakon postupnog povećavanja doza EXJADE tableta za oralnu suspenziju iznad 30 mg/kg, ne može se isključiti povećani rizik bubrežnih štetnih događaja uz filmom obložene tablete u dozama iznad 21 mg/kg.
EXJADE 180 mg granules EU/1/06/356/021 
EXJADE 180 mg granule EU/1/06/356/021
- if you have diarrhoea or vomiting. 
- ako imate zamagljen vid. - ako imate proljev ili povraćate.
EXJADE 90 mg film-coated tablets 
EXJADE 90 mg filmom obložene tablete
- if you experience a combination of any of the following symptoms: rash, red skin, blistering of the lips, eyes or mouth, skin peeling, high fever, flu-like symptoms, enlarged lymph nodes 
- ako primijetite kombinaciju bilo kojih od sljedećih simptoma: osip, crvenu kožu, stvaranje mjehurića na usnicama, očima ili u ustima, ljuštenje kože, vrućicu, simptome nalik gripi,
Medium blue, ovaloid, biconvex film-coated tablet with bevelled edges and imprints (NVR on one face and 180 on the other). 
Srednje plava, ovalna, bikonveksna filmom obložena tableta ukošenih rubova s otisnutim oznakama (NVR na jednoj strani i 180 na drugoj strani).
EXJADE 90 mg film-coated tablets EU/1/06/356/011 
EXJADE 90 mg filmom obložene tablete EU/1/06/356/011
• EXJADE 250 mg tablets are stamped “J 250” on one side and “NVR” on the other. 
• EXJADE 250 mg tablete na jednoj strani imaju otisnutu oznaku „J 250“, a na drugoj strani
EXJADE 360 mg granules EU/1/06/356/022 
EXJADE 360 mg granule EU/1/06/356/022
EXJADE 360 mg film-coated tablets Each film-coated tablet contains 360 mg deferasirox. 
EXJADE 360 mg filmom obložene tablete Svaka filmom obložena tableta sadrži 360 mg deferasiroksa.
For patients already well managed on treatment with deferoxamine, a starting dose of EXJADE dispersible tablets that is numerically half that of the deferoxamine dose could be considered (e.g. a patient receiving 40 mg/kg/day of deferoxamine for 5 days per week (or equivalent) could be transferred to a starting daily dose of 20 mg/kg/day of EXJADE dispersible tablets). 
U bolesnika u kojih je dobra regulacija već postignuta liječenjem deferoksaminom početna doza EXJADE tableta za oralnu suspenziju može iznositi polovicu brojčane vrijednosti doze deferoksamina (npr. bolesnik koji prima 40 mg/kg/dan deferoksamina tijekom 5 dana na tjedan (ili ekvivalentno), može se prebaciti na početnu dnevnu dozu EXJADE tableta za oralnu suspenziju od 20 mg/kg/dan).
EXJADE 360 mg film-coated tablets EU/1/06/356/017 
EXJADE 360 mg filmom obložene tablete EU/1/06/356/017
30 film-coated tablets. 
Filmom obložene tablete 30 filmom obloženih tableta.
EXJADE is also used when deferoxamine therapy is contraindicated or inadequate to treat patients aged 10 years or older who have iron overload associated with their thalassaemia syndromes, but who are not transfusion dependent. 
EXJADE se također koristi za liječenje bolesnika u dobi od 10 godina ili starijih u kojih je došlo do preopterećenja željezom povezanog sa sindromima talasemije neovisnim o transfuziji.
• EXJADE 180 mg film-coated tablets are medium blue and stamped “180” on one side and 
• EXJADE 180 mg filmom obložene tablete su srednje plave i na jednoj strani imaju otisnutu oznaku „180“, a na drugoj strani „NVR“.
For patients already well managed on treatment with deferoxamine, a starting dose of EXJADE granules that is numerically one third that of the deferoxamine dose could be considered (e.g. a patient receiving 40 mg/kg/day of deferoxamine for 5 days per week (or equivalent) could be transferred to a starting daily dose of 14 mg/kg/day of EXJADE granules). 
U bolesnika u kojih je dobra regulacija već postignuta liječenjem deferoksaminom početna doza EXJADE granula može iznositi trećinu brojčane vrijednosti doze deferoksamina (npr. bolesnik koji prima 40 mg/kg/dan deferoksamina tijekom 5 dana na tjedan (ili ekvivalentno), može se prebaciti na početnu dnevnu dozu EXJADE granula od 14 mg/kg/dan).
• Kidney stones 
• Bubrežni kamenci
For patients already well managed on treatment with deferoxamine, a starting dose of EXJADE film-coated tablets that is numerically one third that of the deferoxamine dose could be considered (e.g. a patient receiving 40 mg/kg/day of deferoxamine for 5 days per week (or equivalent) could be transferred to a starting daily dose of 14 mg/kg/day of EXJADE film-coated tablets). 
U bolesnika u kojih je dobra regulacija već postignuta liječenjem deferoksaminom početna doza EXJADE filmom obloženih tableta može iznositi trećinu brojčane vrijednosti doze deferoksamina (npr. bolesnik koji prima 40 mg/kg/dan deferoksamina tijekom 5 dana na tjedan (ili ekvivalentno), može se prebaciti na početnu dnevnu dozu EXJADE filmom obloženih tableta od 14 mg/kg/dan).
• EXJADE 500 mg tablets are stamped “J 500” on one side and “NVR” on the other. 
• EXJADE 500 mg tablete na jednoj strani imaju otisnutu oznaku „J 500“, a na drugoj strani
EXJADE 180 mg film-coated tablets Each film-coated tablet contains 180 mg deferasirox. 
EXJADE 180 mg filmom obložene tablete Svaka filmom obložena tableta sadrži 180 mg deferasiroksa.
OUTER CARTON OF MULTIPACK (including blue box) 
KUTIJA VIŠESTRUKOG PAKIRANJA (UKLJUČUJUĆI PLAVI OKVIR)
OUTER CARTON OF MULTIPACK (INCLUDING BLUE BOX) 
KUTIJA VIŠESTRUKOG PAKIRANJA (uključujući plavi okvir)
While no increase in renal adverse events was observed after dose escalation of EXJADE dispersible tablets to doses above 30 mg/kg in clinical studies, an increased risk of renal adverse events with granule doses above 21 mg/kg cannot be excluded. 
Premda u kliničkim ispitivanjima nije bilo opaženo povećanje bubrežnih štetnih događaja nakon postupnog povećavanja doza EXJADE tableta za oralnu suspenziju iznad 30 mg/kg, ne može se isključiti povećani rizik bubrežnih štetnih događaja uz granule u dozama iznad 21 mg/kg.
Starting dose The recommended initial daily dose of EXJADE dispersible tablets is 20 mg/kg body weight. 
Početna doza Preporučena početna dnevna doza EXJADE tableta za oralnu suspenziju je 20 mg/kg tjelesne težine.
EXJADE 180 mg granules Each sachet contains 180 mg deferasirox. 
EXJADE 180 mg granule Svaka vrećica sadrži 180 mg deferasiroksa.
EXJADE 90 mg granules EU/1/06/356/020 
EXJADE 90 mg granule EU/1/06/356/020
Dark blue, ovaloid, biconvex film-coated tablet with bevelled edges and imprints (NVR on one face and 360 on the other). 
Tamno plava, ovalna, bikonveksna filmom obložena tableta ukošenih rubova s otisnutim oznakama (NVR na jednoj strani i 360 na drugoj strani).
EXJADE 360 mg granules Each sachet contains 360 mg deferasirox. 
EXJADE 360 mg granule Svaka vrećica sadrži 360 mg deferasiroksa.
While no increase in renal adverse events was observed after dose escalation of EXJADE dispersible tablets to doses above 30 mg/kg in clinical studies, an increased risk of renal adverse events with EXJADE dispersible tablet doses above 30 mg/kg cannot be excluded. 
Premda u kliničkim ispitivanjima nije bilo opaženo povećanje bubrežnih štetnih događaja nakon postupnog povećavanja doza EXJADE tableta za oralnu suspenziju iznad 30 mg/kg, ne može se isključiti povećani rizik bubrežnih štetnih događaja uz EXJADE tablete za oralnu suspenziju u dozama iznad 30 mg/kg.
EXJADE granules demonstrate higher bioavailability compared to the EXJADE dispersible tablet formulation. 
EXJADE granule pokazuju višu bioraspoloživost u usporedbi s formulacijom lijeka EXJADE u obliku tableta za oralnu suspenziju.
EXJADE 90 mg film-coated tablets Each film-coated tablet contains 90 mg deferasirox. 
EXJADE 90 mg filmom obložene tablete Svaka filmom obložena tableta sadrži 90 mg deferasiroksa.
• Each sachet of EXJADE 180 mg granules contains 180 mg deferasirox. 
• Svaka vrećica EXJADE 180 mg granula sadrži 180 mg deferasiroksa.
EXJADE 90 mg granules Each sachet contains 90 mg deferasirox. 
EXJADE 90 mg granule Svaka vrećica sadrži 90 mg deferasiroksa.
• Each sachet of EXJADE 360 mg granules contains 360 mg deferasirox. 
• Svaka vrećica EXJADE 360 mg granula sadrži 360 mg deferasiroksa.
<7 mg Fe/g dw or ≤2,000 µg/l 
<7 mg Fe/g težine ili
How to store EXJADE 
Kako čuvati EXJADE
Exjade 360 mg film-coated tablets deferasirox 
Exjade 360 mg filmom obložene tablete deferasiroks
Anxiety, sleep disorder 
anksioznost, poremećaj spavanja Poremećaji živčanog sustava Često:
Breast-feeding while taking EXJADE is not recommended. 
Tijekom primjene lijeka EXJADE ne preporučuje se dojenje.
Not all strengths may be available in your country. 
Na tržištu se ne moraju nalaziti sve jačine lijeka.
Upper gastrointestinal ulceration and haemorrhage have been reported in patients, including children and adolescents, receiving deferasirox. 
U bolesnika koji primaju deferasiroks, uključujući djecu i adolescente, prijavljene su ulceracije i
Exjade 180 mg film-coated tablets deferasirox 
Exjade 180 mg filmom obložene tablete deferasiroks
Light blue, ovaloid, biconvex film-coated tablet with bevelled edges and imprints (NVR on one face and 90 on the other). 
Svijetlo plava, ovalna, bikonveksna filmom obložena tableta ukošenih rubova s otisnutim oznakama (NVR na jednoj strani i 90 na drugoj strani).
The recommended initial daily dose of EXJADE film-coated tablets in patients with non-transfusion-dependent thalassaemia syndromes is 7 mg/kg body weight. 
Preporučena početna dnevna doza EXJADE filmom obloženih tableta u bolesnika sa sindromima talasemije neovisnim o transfuziji je 7 mg/kg tjelesne težine.
• Each sachet of EXJADE 90 mg granules contains 90 mg deferasirox. 
• Svaka vrećica EXJADE 90 mg granula sadrži 90 mg deferasiroksa.
EXJADE 125 mg dispersible tablets Each dispersible tablet contains 125 mg deferasirox. 
EXJADE 125 mg tablete za oralnu suspenziju Svaka tableta za oralnu suspenziju sadrži 125 mg deferasiroksa.
Nervous system disorders Common: 
Poremećaji probavnog sustava Često:
Gastrointestinal perforation 1, acute pancreatitis 
1, akutni pankreatitis
EU/1/06/356/022 30 sachets 
EU/1/06/356/022 30 vrećica
Exjade 360 mg granules in sachet deferasirox 
Exjade 360 mg granule u vrećici deferasiroks
Exjade 180 mg granules in sachet deferasirox 
Exjade 180 mg granule u vrećici deferasiroks
Each dispersible tablet contains 125 mg of deferasirox. 
Svaka tableta za oralnu suspenziju sadrži 125 mg deferasiroksa.
As well as the requirements in the legislation, the following serious ADRs should be forwarded on an expedited basis to the appropriate competent authority as well as summarised in the above reports: o Increase in hepatic enzymes >10x ULN o Serious rise in creatinine o Results of renal biopsies, if available o Cataracts o Hearing loss o Gallstones 
o povišenje jetrenih enzima >10x GGN o ozbiljan porast kreatinina o rezultati biopsije bubrega, ako su dostupni o katarakte o gubitak sluha o žučni kamenci
The recommended initial daily dose of EXJADE granules in patients with non-transfusion-dependent thalassaemia syndromes is 7 mg/kg body weight. 
Preporučena početna dnevna doza EXJADE granula u bolesnika sa sindromima talasemije neovisnim o transfuziji je 7 mg/kg tjelesne težine.
Excipient with known effect: Each dispersible tablet contains 272 mg lactose. 
Svaka tableta za oralnu suspenziju sadrži 272 mg laktoze.
The recommended initial daily dose of EXJADE dispersible tablets in patients with non-transfusion-dependent thalassaemia syndromes is 10 mg/kg body weight. 
Preporučena početna dnevna doza EXJADE tableta za oralnu suspenziju u bolesnika sa sindromima talasemije neovisnim o transfuziji je 10 mg/kg tjelesne težine.
Each tablet contains 360 mg of deferasirox. 
Svaka tableta sadrži 360 mg deferasiroksa.
10 mg/kg/day ≥5 mg Fe/g dw or >800 µg/l 
10 mg/kg/dan ≥5 mg Fe/g težine suhog tkiva jetre ili
Multipack: 300 (10 packs of 30) film-coated tablets 
Filmom obložene tablete Višestruko pakiranje: 300 (10 pakiranja od 30) filmom obloženih tableta
Dispersion in carbonated drinks or milk is not recommended due to foaming and slow dispersion, respectively. 
Zbog stvaranja pjene i sporog suspendiranja, ne preporučuje se priprema suspenzije u gaziranim napicima ni u mlijeku.
Exjade 90 mg film-coated tablets deferasirox 
Exjade 90 mg filmom obložene tablete deferasiroks
EXJADE 250 mg dispersible tablets Each dispersible tablet contains 250 mg deferasirox. 
EXJADE 250 mg tablete za oralnu suspenziju Svaka tableta za oralnu suspenziju sadrži 250 mg deferasiroksa.
EXJADE 125 mg dispersible tablets 
EXJADE 125 mg tablete za oralnu suspenziju
A food-effect study involving administration of the granules to healthy volunteers under fasting conditions and with a low-fat (fat content = approximately 30% of calories) or high-fat (fat content >50% of calories) meal indicated that the AUC and Cmax were slightly decreased after a low-fat meal (by 10% and 11%, respectively). 
= približno 30% kalorija) ili punomasni (sadržaj masti >50% kalorija) obrok ukazalo je na to da su AUC i Cmax bili blago povišeni nakon nemasnog obroka (za 10% odnosno 11%).
EXJADE 250 mg dispersible tablets 
EXJADE 250 mg tablete za oralnu suspenziju
EU/1/06/356/020 30 sachets 
EU/1/06/356/020 30 vrećica
EXJADE 125 mg dispersible tablets deferasirox 
EXJADE 125 mg tablete za oralnu suspenziju deferasiroks
White to slightly yellow, round, flat tablets with bevelled edges and imprints (NVR on one face and J 500 on the other). 
Bijele do žućkaste, okrugle, plosnate tablete ukošenih rubova s otisnutim oznakama (NVR na jednoj strani i J 500 na drugoj strani).
White to slightly yellow, round, flat tablets with bevelled edges and imprints (NVR on one face and J 125 on the other). 
Bijele do žućkaste, okrugle, plosnate tablete ukošenih rubova s otisnutim oznakama (NVR na jednoj strani i J 125 na drugoj strani).
Excipient with known effect: Each dispersible tablet contains 136 mg lactose. 
Svaka tableta za oralnu suspenziju sadrži 136 mg laktoze.
An initial daily dose of 7 mg/kg may be considered for patients who do not require reduction of body iron levels and who are also receiving less than 7 ml/kg/month of packed red blood cells (approximately <2 units/month for an adult). 
Početna dnevna doza od 7 mg/kg može se razmotriti u bolesnika u kojih ne treba snižavati razine željeza u tijelu, a koji također primaju manje od 7 ml/kg/mjesec koncentrata eritrocita (približno <2 jedinice/mjesec za odraslog).
EXJADE 500 mg dispersible tablets Each dispersible tablet contains 500 mg deferasirox. 
EXJADE 500 mg tablete za oralnu suspenziju Svaka tableta za oralnu suspenziju sadrži 500 mg deferasiroksa.
EXJADE 125 mg dispersible tablets EU/1/06/356/001 
EXJADE 125 mg tablete za oralnu suspenziju EU/1/06/356/001
White to slightly yellow, round, flat tablets with bevelled edges and imprints (NVR on one face and J 250 on the other). 
Bijele do žućkaste, okrugle, plosnate tablete ukošenih rubova s otisnutim oznakama (NVR na jednoj strani i J 250 na drugoj strani).
EXJADE 500 mg dispersible tablets EU/1/06/356/005 
EXJADE 500 mg tablete za oralnu suspenziju EU/1/06/356/005
Each tablet contains 180 mg of deferasirox. 
Svaka tableta sadrži 180 mg deferasiroksa.
Dispersible tablets 
Tablete za oralnu suspenziju
30 mg/kg/day 
30 mg/kg/dan
EU/1/06/356/021 30 sachets 
EU/1/06/356/021 30 vrećica
An initial daily dose of 21 mg/kg may be considered for patients who require reduction of elevated body iron levels and who are also receiving more than 14 ml/kg/month of packed red blood cells (approximately >4 units/month for an adult). 
Početna dnevna doza od 21 mg/kg može se razmotriti u bolesnika u kojih treba sniziti povišene razine željeza u tijelu, a koji također primaju više od 14 ml/kg/mjesec koncentrata eritrocita (približno >4 jedinice/mjesec za odraslog).
EXJADE 250 mg dispersible tablets EU/1/06/356/003 
EXJADE 250 mg tablete za oralnu suspenziju EU/1/06/356/003
Each dispersible tablet contains 250 mg of deferasirox. 
Svaka tableta za oralnu suspenziju sadrži 250 mg deferasiroksa.
Each tablet contains 90 mg of deferasirox. 
Svaka tableta sadrži 90 mg deferasiroksa.
An initial daily dose of 30 mg/kg may be considered for patients who require reduction of elevated body iron levels and who are also receiving more than 14 ml/kg/month of packed red blood cells (approximately >4 units/month for an adult). 
Početna dnevna doza od 30 mg/kg može se razmotriti u bolesnika u kojih treba sniziti povišene razine željeza u tijelu, a koji također primaju više od 14 ml/kg/mjesec koncentrata eritrocita (približno >4 jedinice/mjesec za odraslog).
An initial daily dose of 10 mg/kg may be considered for patients who do not require reduction of body iron levels and who are also receiving less than 7 ml/kg/month of packed red blood cells (approximately <2 units/month for an adult). 
Početna dnevna doza od 10 mg/kg može se razmotriti u bolesnika u kojih ne treba snižavati razine željeza u tijelu, a koji također primaju manje od 7 ml/kg/mjesec koncentrata eritrocita (približno <2 jedinice/mjesec za odraslog).
EXJADE 500 mg dispersible tablets 
EXJADE 500 mg tablete za oralnu suspenziju